Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

NTRA - Natera, Inc. So'nggi Yangiliklar | Finranks

Home

/

NTRA

N

Natera, Inc. (NTRA)

NMS – Real vaqt narxi. Valyuta: USD

204.21

+5.07 (2.55%)

Yopilishda: May 12, 2026, 4:00 PM EDT

202.44

-1.77 (-0.87%)

Bozor oldidan: May 13, 2026, 9:18 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.

Natera Q1 Earnings Call Highlights

Natera Q1 Earnings Call Highlights

Natera NASDAQ: NTRA reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women's health and another record quarter in oncology drove the results, while Chief Financial Officer Michael Brophy highlighted continued improvement in realized pricing and reimbursement dynamics.

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

Natera (NTRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.

Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript

Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript

Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript

Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Natera Reports First Quarter 2026 Financial Results

Natera Reports First Quarter 2026 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter.

Natera to Report its First Quarter Results on May 7, 2026

Natera to Report its First Quarter Results on May 7, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its first quarter ended March 31, 2026, after the market closes on May 7, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2026 Financial Results Date: May 7, 2026 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In.

Videolar

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Press-relizlar

Natera Reports First Quarter 2026 Financial Results

Natera Reports First Quarter 2026 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter.

Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academic colleagues, Natera will highlight Prospera's expanding clinical utility in heart and lung transplantation, spanning re.

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (M.

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera's litigation with ArcherDx and Invitae. In a decision issued on April 6, 2026, the Court ordered an ongoing royalty to Natera of 30% on post-injunction revenues from infringing MRD-related product sales that fall within the exceptions to the injun.